Jump to content
Donations Read more... ×
Sign in to follow this  
rasbridge

What Is “Superblood,” and Why Do I Want It?

Recommended Posts

rasbridge
Startup biotech company Rubius Therapeutics wants to use red blood cells to replace missing enzymes and ultimately treat rare diseases and conditions like cancer. So far, the company has raised $220 million to fund their developments.

Much like doctors are using modified T-cells from patients’ immune systems to fight cancer, biotech startup Rubius Therapeutics is aiming to develop targeted disease therapy using red blood cells. Business Insider reports that Rubius’ CEO, Torben Straight Nissen, believes their treatment is “basically superblood,” since their treatments are made using red blood cells rather than chemicals or synthetic materials.

Rubius plans to equip red blood cells with a therapeutic protein that can be tailored to treat a particular condition. Afterwards, they’re infused into the body to begin treating the patient’s condition. Ultimately, this superblood will only account for less than 1 percent of the total amount of blood in a patient’s body.Initially, the company wants to develop superblood therapies that replace missing enzymes in patients suffering from rare diseases, as well as treat cancer and autoimmune disorders like lupus and type 1 diabetes. Unlike T-cell therapy, however, red blood cell therapies don’t need to be as personalized. On their site, Rubius claims they’d only need one universal donor (someone with an O negative blood type) to “generate enough therapeutic doses to treat hundreds to thousands of different patients.”

Rubius is seemingly on track to meet their goals, as it recently finished raising $100 million. This follows the $120 million the company raised in June 2017 from investors.

 

“The addition of this funding further strengthens our foundation and enables us to accelerate the development of our first wave of Red-Cell Therapeutics (RCT) products that are targeting treatment of enzyme deficiencies, cancer and autoimmune disease,” said Nissen in a press statement. “We have assembled an extremely talented team of investors, leadership and advisers, which all share the long-term vision of bringing novel cellular therapies to patients.”

It may be some time before Rubius’ treatments are widely available; after all, they’re currently not much more than a concept. First, these treatments have to be developed, then put through a series of clinical trials to determine their effectiveness. If everything goes well, the superblood could eventually be approved by the U.S. Food and Drug Administration, just as T-cell therapy was last year.

 

Source:  https://futurism.com/superblood-therapy-cancer-disease/

Share this post


Link to post
Share on other sites
Kalju
Posted (edited)

Does once again one spammer is trying to copy the entire Internet?

The half has probably copied already.

At the moment I found 27, maybe is more. All posted within the last hour.

Who still does not know, this is the fastest way to be a veteran soon. Start copying right now, You are done before the morning has come!

And all roads are open to you.

Edited by Kalju

Share this post


Link to post
Share on other sites
rasbridge
18 minutes ago, Kalju said:

Does once again one spammer is trying to copy the entire Internet?

The half has probably copied already.

At the moment I found 27, maybe is more. All posted within the last hour.

I do the same here as elsewhere -- I just read the posts that interest me and ignore posts that do not...

Share this post


Link to post
Share on other sites
jiski
Posted (edited)

Mr. Rasbridge,  You are wise man.  Many thing in world.  We choose good & ignore bad.

Edited by jiski

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

  • Recently Browsing   0 members

    No registered users viewing this page.

×